Collagen-Derived Peptide Reduced AMD Markers in Research
A new peptide treatment showed promise in pre-clinical models, potentially offering an alternative to eye injections.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Would you prefer using eye drops over injections for treating chronic eye conditions?
Researchers have identified a collagen-derived peptide, EB-203, that reduced vascular leakage and choroidal neovascularization in pre-clinical mouse models. This research-stage therapeutic is designed to address the underlying drivers of neovascular age-related macular degeneration.
Why it matters
Current standards for treating neovascular AMD rely on costly, frequent intravitreal injections that carry risks of complications for patients. By exploring peptide-based alternatives, researchers aim to reduce the burden of treatment for this common condition.
In mouse models, EB-203 delivered via 100 µg intravitreal injection or 5% to 10% concentration eyedrops showed superior reduction in choroidal neovascularization compared to aflibercept. Human clinical efficacy remains unknown.
The details
The peptide targets HIF-1α, a protein activated by low oxygen, and subsequently lowers the expression of VEGF, a signaling protein that drives abnormal blood vessel growth in the eye. To simulate hypoxic conditions, the team treated EA.hy926 cells—a human endothelial cell line often used in vascular research—with cobalt chloride. The therapeutic efficacy was demonstrated through reductions in tube formation, cell migration, and invasion within these hypoxic endothelial cell cultures.
Timeline
September 30, 2026: Results regarding the EB-203 study were published.
The Tech Race
Current anti-VEGF therapies represent the established clinical standard for treating neovascular AMD, requiring frequent, invasive ocular injections. The development of EB-203 marks a shift toward topical, peptide-based therapeutics that aim to bypass these procedural bottlenecks.
While this peptide is currently in the research phase, a successful transition to topical administration could eventually replace invasive injection regimens. Patients should note that this study used mouse models and will require extensive human clinical trial data before it becomes a treatment option.
The takeaway
EB-203 shows promise as a mechanism to suppress VEGF-driven eye conditions without surgical intervention. Observers should monitor future registries for the commencement of human safety trials and potential dosage optimization studies.
Further reading
For broader trends in ocular disease research, explore our Biotech section.
More information
View the peer-reviewed research article for full technical findings.
Source note: This article includes information reported by Nature.
Live Poll
Would you prefer using eye drops over injections for treating chronic eye conditions?
